FDA Accepts Supplemental Biologics License Application for Hadlima for Interchangeability With Humira
The sBLA was based on data from a clinical study assessing the pharmacokinetics of switching between adalimumab and adalimumab-bwwd for patients with moderate to severe plaque psoriasis.
Source: pharmacytimes.com